Mathematical Modeling of Non-Small-Cell Lung Cancer Biology through the Experimental Data on Cell Composition and Growth of Patient-Derived Organoids

被引:3
|
作者
Sulimanov, Rushan [1 ]
Koshelev, Konstantin [1 ,2 ]
Makarov, Vladimir [1 ]
Mezentsev, Alexandre [1 ,3 ]
Durymanov, Mikhail [1 ,3 ]
Ismail, Lilian [3 ]
Zahid, Komal [3 ]
Rumyantsev, Yegor [1 ]
Laskov, Ilya [1 ]
机构
[1] Yaroslav The Wise Novgorod State Univ, Med Informat Lab, Veliky Novgorod 173003, Russia
[2] Russian Acad Sci, Ivannikov Inst Syst Programming, Moscow 109004, Russia
[3] Moscow Inst Phys & Technol, Sch Biol & Med Phys, Dolgoprudnyi 141701, Russia
来源
LIFE-BASEL | 2023年 / 13卷 / 11期
关键词
mathematical modeling; non-small-cell lung cancer; flow cytometry; cell composition; tumor-associated macrophages; cytotoxic T-lymphocytes; adenocarcinoma; cancer cells; cancer-associated fibroblasts; EXPRESSION;
D O I
10.3390/life13112228
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Mathematical models of non-small-cell lung cancer are powerful tools that use clinical and experimental data to describe various aspects of tumorigenesis. The developed algorithms capture phenotypic changes in the tumor and predict changes in tumor behavior, drug resistance, and clinical outcomes of anti-cancer therapy. The aim of this study was to propose a mathematical model that predicts the changes in the cellular composition of patient-derived tumor organoids over time with a perspective of translation of these results to the parental tumor, and therefore to possible clinical course and outcomes for the patient. Using the data on specific biomarkers of cancer cells (PD-L1), tumor-associated macrophages (CD206), natural killer cells (CD8), and fibroblasts (alpha SMA) as input, we proposed a model that accurately predicts the cellular composition of patient-derived tumor organoids at a desired time point. Combining the obtained results with "omics" approaches will improve our understanding of the nature of non-small-cell lung cancer. Moreover, their implementation into clinical practice will facilitate a decision-making process on treatment strategy and develop a new personalized approach in anti-cancer therapy.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Drug screening of non-small cell lung cancer patient-derived organoids in a microwell platform
    Luan, Qiyue
    Pulido, Ines
    Zhou, Jian
    Shimamura, Takeshi
    Papautsky, Ian
    CANCER RESEARCH, 2023, 83 (07)
  • [2] Patient-Derived Tumoroid for the Prediction of Radiotherapy and Chemotherapy Responses in Non-Small-Cell Lung Cancer
    Nounsi, Anasse
    Seitlinger, Joseph
    Ponte, Charlotte
    Demiselle, Julien
    Idoux-Gillet, Ysia
    Pencreach, Erwan
    Beau-Faller, Michele
    Lindner, Veronique
    Balloul, Jean-Marc
    Quemeneur, Eric
    Burckel, Helene
    Noel, Georges
    Olland, Anne
    Fioretti, Florence
    Falcoz, Pierre-Emmanuel
    Benkirane-Jessel, Nadia
    Hua, Guoqiang
    BIOMEDICINES, 2023, 11 (07)
  • [3] Vascularization of Patient-Derived Tumoroid from Non-Small-Cell Lung Cancer and Its Microenvironment
    Seitlinger, Joseph
    Nounsi, Anasse
    Idoux-Gillet, Ysia
    Pujol, Eloy Santos
    Le, Helene
    Grandgirard, Erwan
    Olland, Anne
    Lindner, Veronique
    Zaupa, Cecile
    Balloul, Jean-Marc
    Quemeneur, Eric
    Massard, Gilbert
    Falcoz, Pierre-Emmanuel
    Hua, Guoqiang
    Benkirane-Jessel, Nadia
    BIOMEDICINES, 2022, 10 (05)
  • [4] Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation
    Kang, Han Na
    Choi, Jae Woo
    Shim, Hyo Sup
    Kim, Jinna
    Kim, Dae Joon
    Lee, Chang Young
    Hong, Min Hee
    Park, Seong Yong
    Park, A-Young
    Shin, Eun Joo
    Lee, Seo Yoon
    Pyo, Kyoung-Ho
    Yun, Mi Ran
    Choi, Hun Mi
    Lee, Sung Sook
    Kim, Seok-Young
    Lee, Hanna
    Paik, Soonmyung
    Cho, Byoung Chul
    Lee, Jin Gu
    Kim, Hye Ryun
    LUNG CANCER, 2018, 124 : 168 - 178
  • [5] Non-small cell lung cancer patient-derived organoids as high-throughput chemotherapy testing platforms
    Manjunath, Yariswamy
    Suvilesh, Kanve Nagaraj
    Innokenteva, Iuliia
    Warren, Wesley
    Kimchi, Eric T.
    Staveley-O'Carroll, Kevin F.
    Li, Guangfu
    Mitchem, Jonathan B.
    Kaifi, Jussuf T.
    CANCER RESEARCH, 2022, 82 (12)
  • [6] Histological and Genetic Parental Tumor Characteristics are Conserved in Patient-derived Non-small Cell Lung Cancer Organoids
    Werner, R. S.
    Jang, J. -H.
    Kirschner, M. B.
    Opitz, I.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S614 - S614
  • [7] Establishment and Long-Term Expansion of Small Cell Lung Cancer Patient-Derived Tumor Organoids
    Choi, Seon Young
    Cho, Yong-Hee
    Kim, Da-Som
    Ji, Wonjun
    Choi, Chang-Min
    Lee, Jae Cheol
    Rho, Jin Kyung
    Jeong, Gi Seok
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (03) : 1 - 13
  • [8] Establishment and Characterization of Patient-Derived Xenograft Model of Non-Small-Cell Lung Cancer Derived from Malignant Pleural Effusions
    Liao, Hong
    Zhou, Shixin
    Chen, Si
    Li, Jun
    Zhang, Zongqi
    Meng, Ling
    Liu, Qiliang
    Wu, Yuan
    He, Yuanqiao
    Li, Ming
    CANCER MANAGEMENT AND RESEARCH, 2023, 15 : 165 - 174
  • [9] Establishment of patient-derived tumor spheroids for non-small cell lung cancer
    Zhang, Zengli
    Wang, Huiqian
    Deng, Qifeng
    Xing, Yufei
    Xu, Zhonghua
    Lug, Chun
    Luo, Dongdong
    Xu, Longjiang
    Xia, Wei
    Zhou, Caicun
    Shi, Minhua
    PLOS ONE, 2018, 13 (03):
  • [10] Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?
    Merk, Johannes
    Rolff, Jana
    Becker, Michael
    Leschber, Gunda
    Fichtner, Iduna
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2009, 36 (03) : 454 - 459